News | News By Subject | News by Disease News By Date | Search News

Gout News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AstraZeneca PLC (AZN) Unloads Gout Drug Rights to Grunenthal in $230 Million+ Deal     6/2/2016
Ironwood (IRWD) to Fork Over Up to $256 Million Plus Royalties to AstraZeneca PLC (AZN) for U.S. Rights to Gout Drug     4/26/2016
FDA Greenlights AstraZeneca PLC (AZN)'s Gout Drug Zurampic     12/23/2015
FDA Panel Votes in Favor of AstraZeneca PLC (AZN)'s Gout Drug Lesinurad     10/26/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
With Promising New Gout Treatment In Its Pipeline, 2015 Will Be Big Year For CymaBay Therapeutics     11/14/2014
AstraZeneca PLC (AZN) Gets A Pipeline Boost From Good Phase 3 Gout Drug Results     8/13/2014
AstraZeneca PLC (AZN) Chases Demon Disease Cure, Potential To Be A Blockbuster Drug     2/17/2014
Savient Pharmaceuticals, Inc. (SVNT) Drug Sales Drop     3/20/2013
Novartis AG (NVS)'s Ilaris Cleared for Gouty Arthritis in EU     3/1/2013
FDA Rejects Expanded Use of Regeneron Pharmaceuticals, Inc. (REGN) Drug for Gout     8/1/2012
Biocryst Pharmaceuticals (BCRX) Reveals Favorable Results From Ulodesine in Phase II Clinical Trials     7/24/2012
Savient Pharmaceuticals, Inc. (SVNT) Reveals KRYSTEXXA Phase III Data Improves HRQOL in RCG Patients     7/2/2012

News from Around the Web
Portable Holographic Microscope For Diagnosing Gout, UCLA Study     7/29/2016
Sleep Apnea Tied To Gout Flares, Boston University Clinical Epidemiology Research And Training Unit Study     10/30/2015
Eating Cherries "Could Cut Gout," Boston University Study     10/1/2012
New Drug May Relieve Severe, Tough-to-Treat Gout, University of Chicago Study     8/17/2011
Soda, OJ May Increase Risk of Gout, Boston University School of Medicine Study     11/10/2010
Canakinumab Prevents Flares in Gout Patients, Robert Wood Johnson University Hospital Study     6/21/2010
Gout Chemical Slows Parkinson's, Harvard Medical School Study     10/13/2009
Vitamin C Wards Off Gout In Men, University of British Columbia Study     3/10/2009
New Drug May Treat Gout, Duke University Medical Center Researchers Find     10/27/2008
New Genes Linked To Gout, National Heart, Lung, and Blood Institute Study     10/1/2008
Gout Drug Cuts Teen High Blood Pressure; Allopurinol Lowers Teen Blood Pressure but Isn't the Ultimate Answer, Baylor College of Medicine Researcher Says     8/27/2008
Gene "Linked To Higher Gout Risk" Identified by MRC Human Genetics Researchers     3/10/2008
Soft Drinks Worse Than Hard Liquor for Gout, but Diet Sodas OK     2/1/2008
Coffee Consumption May Lower Blood Uric Acid Levels -- The Precursor of Gout     5/25/2007
Alcohol May Trigger Gout Attacks     9/27/2006

Press Releases
Ironwood (IRWD) Announces FDA Approval Of DUZALLO (Lesinurad And Allopurinol) For The Treatment Of Hyperuricemia In Patients With Uncontrolled Gout     8/21/2017
Selecta (SELB) Reports Data From Ongoing Phase II Trial Of Lead Candidate, SEL-212, In Development For Chronic Severe Gout     6/15/2017
Horizon Pharma (HZNP) Presents New Data Analyses Further Demonstrating Clinical Benefit Of KRYSTEXXA (Pegloticase) In Patients With Uncontrolled Gout     6/14/2017
Horizon Pharma (HZNP) Release: Epidemiologic Study Findings Show Over 400 Percent Increase In Gout Patient Hospitalizations Since 1993     6/14/2017
Arthritis Research Canada Release: Study Finds First Evidence The DASH Diet Will Lower Risk Of Gout     5/12/2017
Sobi Release: First Patient Randomized In A Phase II Study Evaluating The Safety And Efficacy Of Anakinra In The Treatment Of Acute Gout     1/11/2017
Ironwood (IRWD) Announces New Drug Application For DUZALLO (Fixed-Dose Combination Of Lesinurad And Allopurinol) Has Been Accepted For FDA Review     1/4/2017
Horizon Pharma (HZNP) Presents Data On KRYSTEXXA (Pegloticase) For The Management Of Refractory Chronic Gout At The 2016 ACR/ARHP Annual Meeting     11/14/2016
Relburn-Metabolomics Files Patents On Bifunctional Nanomolar Inhibitors Of Gout Target Enzymes     10/17/2016
Ironwood (IRWD) Announces U.S. Availability Of ZURAMPIC (lesinurad) 200 mg Tablets For Patients With Uncontrolled Gout     10/3/2016
TWi Biotechnology Announces Last Patient Enrolled In Phase 2 Study Of AC-201CR For Gout Treatment     6/27/2016
Gensco Laboratories Launches The First Transdermal Medication For Acute Gout Flares With Copay And Cash Pay Assistance For Patients     3/3/2016
TWi Biotechnology Inc. Reports Positive Interim Results From AC-201 CR Phase 2 Proof-Of-Concept Study In Gout Patients     12/28/2015
Select Biosciences Announces Dosing Of First Patient In Phase 1b Clinical Trial Of SEL-212, Designed To Be The First Non-Immunogenic Biologic Treatment For Gout     12/23/2015
AstraZeneca PLC (AZN) Presents Positive Update On Lesinurad Renal Data In Gout Patients     11/9/2015